Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Inventory (2017 - 2026)

Organogenesis Holdings has reported Inventory over the past 9 years, most recently at $29.6 million for Q4 2025.

  • For Q4 2025, Inventory rose 13.0% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $29.6 million, up 13.0%, while the annual FY2025 figure was $29.6 million, 13.0% up from the prior year.
  • Inventory for Q4 2025 was $29.6 million at Organogenesis Holdings, down from $39.6 million in the prior quarter.
  • Over five years, Inventory peaked at $39.6 million in Q3 2025 and troughed at $22.7 million in Q1 2022.
  • A 5-year average of $27.7 million and a median of $27.4 million in 2024 define the central range for Inventory.
  • Biggest five-year swings in Inventory: decreased 23.5% in 2022 and later skyrocketed 46.41% in 2025.
  • Year by year, Inventory stood at $25.0 million in 2021, then fell by 0.96% to $24.8 million in 2022, then increased by 14.0% to $28.3 million in 2023, then fell by 7.2% to $26.2 million in 2024, then grew by 13.0% to $29.6 million in 2025.
  • Business Quant data shows Inventory for ORGO at $29.6 million in Q4 2025, $39.6 million in Q3 2025, and $33.0 million in Q2 2025.